MSD Ireland to invest €280 million and create 330 new jobs in Carlow and Cork

MSD currently employs over 1,600 people across four sites in Ireland – in Carlow, Cork, Dublin and Tipperary

Must Read

How to choose an effective DDoS mitigation plan

There are several flavours from which to choose when selecting an effective DDoS mitigation strategy. Most enterprises opt for one of the protection flavours (always-on or on-demand)

How tech bolster security of online gaming platforms

The rise of online gaming and is evident throughout the world’s financial capitals with the UK, US, and a few other European nations at the forefront

Explained: The evolving nature of cybersecurity threats

Concerns such as hacking and the presence of computer viruses have existed for decades in one form or another. As technology evolved over the years, so did the cybersecurity  threats themselves.

Global biopharmaceutical firm MSD, known as Merck in the U.S. and Canada said that it will create 330 new jobs and invest €280 million over the next three years at two of its Irish manufacturing sites.

The new jobs, which will be created in Carlow and Cork, are as a result of increased global demand for MSD’s medicines and vaccines produced in Ireland, while the investment will see both sites expand production facilities and capacity to meet that demand, said company in a statement.

MSD in Brinny, Co. Cork is an integrated site for the development, testing and manufacturing of biologics, specialising in the fermentation, purification and sterile filling of biotech products. More than 200 new hires will be needed to meet demand for its work on some of the company’s important treatments – medicines for lung cancer, melanoma, hepatitis C and rheumatoid arthritis, said company.

MSD in Carlow which is the company’s first stand-alone vaccine and biologics facility outside the US, plans to create 120 new roles. Carlow also is an important link in MSD’s network of sites producing our new immuno-oncology treatment for the global market.

Available roles at the sites include technical, engineering, biochemistry, biology, quality and operations positions, said MSD.

“Our Irish sites are involved in the production of over 50% of MSD’s global top 20 products, exporting to over 60 countries worldwide and helping lead the development of new life-changing medicines for patients, including MSD’s new treatments for cancer and hepatitis C,” said Ger Brennan, Managing Director of MSD Human Health in Ireland.

MSD currently employs over 1,600 people across four sites in Ireland – in Carlow, Cork, Dublin and Tipperary. Its Irish operations, encompassing manufacturing, commercial, global financial services and marketing facilities, had a turnover of €4.7 billion in 2016.

MSD provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immuno-oncology, infectious diseases and vaccines.

MSD maintains headquarters for the company and manufacturing division in the U.S.

Subscribe to receive the day's headlines from Tech Observer straight in your inbox

Leave a Reply

*The moderation of comments is automated and not cleared manually by techobserver.in. Embedding of any link and use of abusive or unparliamentary language are prohibited.
- Advertisement -

Latest in TECH

Sapience Analytics signs distribution agreement with Redington

Sapience Analytics and Redington said that they have entered into a distribution agreement where latter will resell the Sapience Vue solution through its network of over 30,000 channel partners, system integrators, and value-added resellers countrywide.
- Advertisement -SAP Hana

Related Articles